SCHEMBL3828611

SCHEMBL3828611

NN=C(N)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.65
MEN1 O00255 1/20 0.65
POLB P06746 2/20 0.54
GRIN2B Q13224 3/20 0.52
GRIN1 Q05586 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CYP2D6 P10635 1/20 0.48
HIF1A Q16665 1/20 0.48
BLM P54132 2/20 0.48
RECQL P46063 2/20 0.48
CYP2C19 P33261 2/20 0.48
MAPT P10636 2/20 0.48
F2 P00734 1/20 0.48
F10 P00742 1/20 0.48
F12 P00748 1/20 0.48
F7 P08709 1/20 0.48
F3 P13726 1/20 0.48
PKM P14618 1/20 0.48
CYP3A4 P08684 1/20 0.48
PARP1 P09874 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11323612 1.00 KMT2A (0.65) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL14125504 1.00 KMT2A (0.65) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL19791239 0.80 PRSS1 (0.60) KMT2AMEN1GRIN2BPLAUPRSS1
SCHEMBL18938347 0.80 KMT2A (0.61) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL24136574 0.79 KMT2A (1.00) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL139363 0.79 KMT2A (1.00) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL24662980 0.79 KMT2A (1.00) KMT2AMEN1POLBGRIN2BGRIN1
Benzamidoxime SCHEMBL102483 0.78 KMT2A (0.58) KMT2AMEN1POLBGRIN2BGRIN1
Benzamidoxime SCHEMBL872652 0.78 KMT2A (0.58) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL22872296 0.78 KMT2A (0.58) KMT2AMEN1POLBGRIN2BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3366311-B1 HYDRAZINO-1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM 3M INNOVATIVE PROPERTIES CO (US) 2020-02-26 EP disclosed
US-10406142-B2 Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom 3M LNNOVATIVE PROPERTIES COMPANY (US) 2019-09-10 US disclosed
EP-3366311-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM 3M Innovative Properties Co. (US) 2018-08-29 EP disclosed
EP-2718292-B1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM 3M INNOVATIVE PROPERTIES CO (US) 2018-03-14 EP disclosed
US-20170173164-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2017-06-22 US disclosed
US-9585968-B2 Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom 3M INNOVATIVE PROPERTIES COMPANY (US) 2017-03-07 US disclosed
CN-104487433-B Triazolone compounds as mPGES-1 inhibitors 格兰马克药品股份有限公司 2016-12-07 CN disclosed
US-20150352218-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM 3M INNOVATIVE PROPERTIES COMPANY 2015-12-10 US disclosed
US-9107958-B2 Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-08-18 US disclosed
CN-104487433-A Triazolone compounds as mpges-1 inhibitors GLENMARK PHARMACEUTICALS SA 2015-04-01 CN disclosed
US-20140286988-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-25 US disclosed
EP-2718292-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM 3M Innovative Properties Company (US) 2014-04-16 EP disclosed
WO-2012167081-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-12-06 WO disclosed
EP-2102175-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR Merck Patent GmbH (DE) 2009-09-23 EP disclosed
CN-101426792-A Pyrazolopyrimidines as therapeutic agents ABBOTT GMBH & CO KG (DE) 2009-05-06 CN disclosed
WO-2008086857-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR MERCK PATENT GMBH (DE) 2008-07-24 WO disclosed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP disclosed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO disclosed
US-4262113-A INTERFACIAL POLYMERIZATION TO FORM HIGH MOLECULAR WEIGHT AROMATIC POLYCARBONATE GENERAL ELECTRIC COMPANY (US) 1981-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140286988-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM IL15, IL2, HNMT KMT2A 423/4885MEN1 3424/4885POLB 3773/4885
US-20170173164-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM IL15, IL2, HNMT KMT2A 423/4885MEN1 3424/4885POLB 3773/4885
US-10406142-B2 Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom IL15, IL2, HNMT KMT2A 423/4885MEN1 3424/4885POLB 3773/4885
US-20150352218-A1 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM IL15, IL2, HNMT KMT2A 423/4885MEN1 3424/4885POLB 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.